The German biotechnology industry can look back on a very successful year:

• The raising of capital rises to 3.1 billion euros - an increase of 146 percent compared to the record year 2018 . However, as in previous years, the financing in 2020 was primarily determined by individual events. BioNTech and CureVac, both of which became known to the general public with the development of vaccines against COVID19, contributed more than half of the total risk capital raising with 1.55 billion euros.
• Two IPOs by companies CureVac and Immatics in the USA. They took in 215 and 224 million euros respectively, for a total of 439 million euros. The two new additions to the stock exchange were partly responsible for the fact that the 23 listed companies were able to record a significant increase in all key figures. In comparison to the previous year, sales rose by 43 percent to 3.2 billion euros. The number of employees increased by 18 percent to 13,995. When it comes to spending on research and development, the listed biotechs can even report growth of two thirds to 1.4 billion euros.
• Revenue, number of employees and spending on research and development are increasing significantly at listed biotech companies
• Risk capital in Germany is increasing significantly - the United Kingdom is the European frontrunner
• The number of alliances is falling, but the financial volume for the at the stock listed companies is increasing by 57 percent to 6.9 billion euros.
• 7,8 Bill € are invested by the member companies of the VFA (Association of research-based pharmaceutical companies) annually in drug research in Germany. These also include subsidiaries of foreign pharmaceutical companies such as Amgen or Daiichi Sankyo.
• In Germany 19,000 employees were working in 2019 for the research and development of these pharmaceutical companies.
• The German pharmaceutical industry has brought 32 drugs with new active ingredients on the market in 2020.That's seven more than in 2019.
• The new drugs also include the first vaccine against Covid-19 and ten new anti-cancer drugs.
• The German export of pharmaceutical products was increased since 2008 by almost 90% to over EUR 80 billion in the year 2019.
• 15% of all pharmaceuticals exported worldwide in 2019came from Germany. Based on these data the German Pharmaceutical industry belongs among the most important exporters. In Europe follows France and Italy (6%), United Kingdom (4%) and Spain (2%).
• While general German exports in the 2nd quarter of 2020 fell by a quarter due to the corona crisis,exports of pharmaceuticals rose 7% compared to the previous year.
• 4 Bill.Euros was the value of the pharmaceutical exports from Germany to China and India in 2019.In thisperiod the imports from these regions were at around 2 billion Euros..